Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
A pretherapeutic radiation-prediction score to identify Lu-177-PSMA-617 patients at increased radiation risk for nursing staff (EANM 2026) - Sep 29, 2026 - Abstract #EP-0899; "A simple pretherapeutic score based on eGFR, PSA, and administered activity identified Lu-177-PSMA-617 patients at increased risk of higher first-day radiation levels. It may support radiation-aware nursing workflow planning." 
Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
K. Hansen 1; A. Haslauer 1; S. Boyaci 1; M. Eiber 1, 2; M. C. M. Gammel 1
 
Sep 29, 2026
 
Prev Next